The Weill Cornell Medicine Interstitial Lung Disease (ILD) Program is dedicated to providing comprehensive and personalized care to our patients living with ILD and pulmonary fibrosis. We work with an expert multidisciplinary team of providers to ensure that we provide an accurate diagnosis, offer patients the most up-to-date information about their disease and treatment options, and develop a patient-centered care plan that aligns with our patients’ values and goals.
• Diagnose and treat patients with all forms of ILD
• Provide patients with the most up-to-date information about diagnosis and treatment options based on cutting edge research in the field
• Work closely with our expert colleagues in other departments across Weill Cornell Medicine in order to provide comprehensive multidisciplinary care
• Develop care plans in partnership with our patients and their families that focus on improving the lives of patients with ILD
• Offer patients access to the latest clinical trials in the field
• Provide our trainees with the tools to effectively diagnose and manage ILD through intense immersion in the ILD program
• Educate the wider medical community about ILD symptoms, early detection and appropriate referral to our center
Partner with investigators at our institution, across the nation, and world-wide to conduct research aimed at improving our understanding of ILD, increasing available safe therapeutic options, and improving the quality of life for our patients
At Weill Cornell Medicine, we diagnose and treat all forms of interstitial lung disease and pulmonary fibrosis, including:
• Alveolar hemorrhage syndromes
• Bronchiolitis obliterans
• Connective tissue disease associated ILD (anti-synthetase syndrome, dermatomyositis, mixed connective tissue disease, polymyositis, rheumatoid arthritis, scleroderma, Sjogren’s syndrome and inflammatory bowel disease)
• Combined pulmonary fibrosis and emphysema
• Cryptogenic organizing pneumonia
• Drug-induced ILD
• Eosinophilic granulomatosis with polyangiitis
• Eosinophilic pneumonia
• Familial pulmonary fibrosis
• Granulomatosis with polyangiitis (Wegener’s granulomatosis)
• Idiopathic pulmonary fibrosis (IPF)
• Hypersensitivity pneumonitis
• Langerhans cell histiocytosis
• Lymphocytic Interstitial Pneumonia
• Nonspecific interstitial pneumonia
• Pleuroparenchymal fibroelastosis
• Pneumoconioses and occupational lung diseases
• Progressive fibrotic ILD
• Unclassifiable ILD
Please bring your previous chest imaging (reports and images on a disc), pulmonary function test reports, lung biopsy report and glass slides (if done), if not already submitted prior to the visit.
Your provider will perform a comprehensive history and physical examination, review any prior testing and imaging you have had related to your diagnosis. You may be asked to undergo additional testing to help us make the diagnosis.
Interstitial lung disease can take on a variety of forms. Often, understanding if a patient has interstitial lung disease and what caused it can be a challenge. It requires taking a detailed history, performing a thorough physical exam, ordering the appropriate testing, and reviewing imaging and biopsy results (if performed) with a team of specialists with expertise in ILD. Our team of ILD providers work closely as part of a multidisciplinary group of specialists in order to provide our patients with an accurate diagnosis. We meet weekly to discuss cases at our multidisciplinary conference.
Our specialists work closely with a group of experts from specialties across Weill Cornell Medicine and NewYork-Presbyterian to diagnose and manage our patients’ lung disease and any related health problems.
We also work closely with patients’ referring pulmonologists and primary care providers to develop and coordinate a personalized care plan.
Weill Cornell Medicine serves as the primary site for several ongoing research studies aimed at improving our understanding of ILD and developing treatments. (CLEANUP-IPF; PRECISIONS)
Weill Cornell Medicine is a participating site in several ongoing national and global clinical trials and registries in ILD. (Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO); Pulmonary Fibrosis Foundation Registry).
Our physicians are active in leading many of these studies with support from the National Institute of Health and industry partners.
See our full list of actively enrolling research studies here
NYP #1 hospital in New York, #4 Hospital in the nation
Pulmonary Fibrosis Foundation (PFF) designated care center
Link to Pulmonary Fibrosis Foundation
Link to American Thoracic Society patient resources
Link to Clinical Trials .gov